Novartis today announced updated data from the Phase III COMBI-v study showing a significant overall survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar(dabrafenib) + Mekinist (trametinib) compared to vemurafenib monotherapy
Featured News & Press Releases cover by this report include: Jan 26, 2015: Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium; Jan 08, 2015: Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy
Study 011 and Long Term Extension Study; Dec 22, 2014: Amicus Therapeutics to Present Program Updates at 33rd Annual J.
Initial treatment with any fluoroquinolone was the only positive predictor of early clinical response, and use of macrolide monotherapy
was the only negative predictor of early clinical response," Dr.
At week 50, REMICADE showed similar significant therapeutic benefit over azathioprine monotherapy
The prompt addition of infliximab to methotrexate in patients with early rheumatoid arthritis who did not respond to brief monotherapy
produced clinically superior results at I year, compared with adjuvant therapy with conventional disease-modifying antirheumatic drugs, according to the ongoing SWEFOT trial.
In combination with either valproate or lithium, olanzapine therapy was effective in treating patients with coexisting manic and depressive symptoms who did not respond adequately to lithium or valproate monotherapy
, said Robert W.
Although clinical studies showing marginal efficacy of didanosine monotherapy
were used to get approval for the drug's registration, monotherapy
is no longer considered optimal use of this or any antiretroviral drug.
They are part of a broader set of data from a series of monotherapy
and combination therapy trials with ARQ 501 that support our Phase 2 program, initiated earlier this year.
zonisamide) has today been approved by Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, for the monotherapy
treatment of partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy.
A Marketing Authorisation Application (M) for UMEC monotherapy
(55 mcg delivered dose) has been submitted to the European Medicines Agency (EMA), for a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
But it voted 4-4, with 1 abstention, that the drug was acceptably safe "in certain circumstances" when used as a monotherapy
The purpose of the study is to evaluate whether Visudyne combined with Lucentis is not inferior to Lucentis monotherapy
with respect to the mean change from baseline in visual acuity (VA) and to evaluate the proportion of patients with a treatment-free interval of at least three months duration after Month 2.